title: Long-term survival after excision of a giant esophageal gastrointestinal stromal tumor with imatinib mesylate resistance: report of a case.
abstract: A 69-year-old woman underwent 4 months of imatinib mesylate chemotherapy for a diagnosed gastrointestinal stromal tumor of the esophagus. This treatment was suspended because of its side effects and because radiological examinations showed that the tumor had not changed or had even increased slightly in size. Thus, we performed esophagectomy via left thoracotomy and removed a tumor that measured 18 × 17 × 10 cm. Immunohistochemical examination revealed positive reactions for c-kit and CD34, suggestive of a high-risk malignancy. The patient was discharged from hospital on postoperative day 30, and has remained well with no sign of tumor recurrence for more than 5 years, without adjuvant chemotherapy.
authors.affiliation: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Nanakuma 7-45-1, Johnan-ku, Fukuoka, Fukuoka, 814-0180, Japan, takeno@fukuoka-u.ac.jp.
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Takeno
authors.forename: Mirei
authors.initials: M
authors.lastname: Kamei
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ono
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Moroga
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Kawahara
authors.forename: Ippei
authors.initials: I
authors.lastname: Yamana
authors.forename: Kenji
authors.initials: K
authors.lastname: Maki
authors.forename: Toyoo
authors.initials: T
authors.lastname: Shiroshita
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yamashita
mesh_terms: D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000032:analysis; D019008:Drug Resistance, Neoplasm; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000601:surgery*; D016629:Esophagectomy; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000235:genetics / Q000601:surgery*; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects; D012306:Risk; D013908:Thoracotomy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit